Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.

Abstract

Background:

Vaccine-induced immunity is essential for controlling the COVID-19 pandemic. Data on humoral and cellular immunogenicity and safety of different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases (RMDs) are limited.

Methods:

A single center observational study evaluated the immunogenicity and safety of the two-dose regimen of the BBIBP-CorV inactivated, Gam-COVID-Vac and AZD1222 adenovirus-based, and BNT162b2 and mRNA-1273 mRNA-based vaccines in patients with RMDs (n = 89) compared with healthy controls (n = 74). Neutralizing anti-RBD (receptor binding domain) specific antibodies and SARS-CoV-2 specific T-cell response were measured one and four months after the second vaccine dose in parallel with vaccination efficacy and safety.

Results:

Disease-specific comparison showed that antibody response at four months was higher in spondylarthropathies compared to rheumatoid arthritis and autoimmune RMDs. Risk factors for reduced immunogenicity included longer disease duration, positive immunoserological profile and anti-CD20 therapy of patients. The rate of positive anti-RBD antibody response for healthy controls versus patients after 4 months post vaccination was 69% vs. 55% for the inactivated viral vaccine BBIBP-CorV, 97% vs. 53% for the pooled data of adenovirus vector-based vaccines Gam-COVID-Vac and AZD1222, or 100% vs. 81% for the pooled data of mRNA vaccines BNT162b2 and mRNA-1273, respectively. Patients who received the Gam-COVID-Vac or mRNA-1273 vaccines had a higher proportion of TNF-α producing CD4+ T-cells upon SARS-CoV-2 antigen stimulation compared to the inactivated viral vaccine.

Conclusion:

All five investigated vaccines were immunogenic in the majority of patients and healthy controls with variable antibody and T-cell response and an acceptable safety profile.

• Authors: Gábor J Szebeni, Nikolett Gémes, Dániel Honfi, Enikő Szabó, Patrícia Neuperger, József Á Balog, Lajos I Nagy, Zoltán Szekanecz, László G Puskás, Gergely Toldi, Attila Balog
• Journal: Frontiers in immunology (Front Immunol) Vol. 13 Pg. 846248 ( 2022) ISSN: 1664-3224 [Electronic] Switzerland
• PMID: 35432314 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 Szebeni, Gémes, Honfi, Szabó, Neuperger, Balog, Nagy, Szekanecz, Puskás, Toldi and Balog.

Chemical References

• Antibodies, Viral
• COVID-19 Vaccines
• mRNA Vaccines
• ChAdOx1 nCoV-19
• BNT162 Vaccine

Topics

• Antibodies, Viral
• BNT162 Vaccine
• COVID-19 (immunology, prevention & control)
• COVID-19 Vaccines (adverse effects, immunology, therapeutic use)
• ChAdOx1 nCoV-19
• Humans
• Musculoskeletal Diseases
• Pandemics
• SARS-CoV-2
• mRNA Vaccines